Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

14-ICML Satellite symposia programs and abstracts (updated on May 21 2017)

(2017)   HEMATOLOGICAL ONCOLOGY

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017

(2017) William G. Wierda et al.   Journal of the National Comprehensive Cancer Network

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

(2017) J. J. Shatzel et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib

(2017) Khai Li Chai et al.   LEUKEMIA & LYMPHOMA

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies)

(2016) B. Eichhorst et al.   ANNALS OF ONCOLOGY

AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib

(2016) Inhye E. Ahn et al.   BLOOD

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders

(2016) Stephen P. Mulligan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

(2016) L de Zwart et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Ibrutinib in the real world patient: many lights and some shades

(2016) P. Ghia et al.   HAEMATOLOGICA

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

(2016) M. Winqvist et al.   HAEMATOLOGICA

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

(2016)   HAEMATOLOGICA

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

(2016) C. Vitale et al.   HAEMATOLOGICA

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

(2016) Michael L Wang et al.   LANCET ONCOLOGY

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

(2016) Susan O'Brien et al.   LANCET ONCOLOGY

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

(2016) Asher Chanan-Khan et al.   LANCET ONCOLOGY

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

(2016) Heidi D. Finnes et al.   LEUKEMIA & LYMPHOMA

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

(2016) Tait D. Shanafelt et al.   LEUKEMIA & LYMPHOMA

Ibrutinib in the real world patient: many lights and some shades

(2016) P. Ghia et al.   HAEMATOLOGICA

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

(2016) M. Winqvist et al.   HAEMATOLOGICA

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

(2016)   HAEMATOLOGICA

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

(2016) C. Vitale et al.   HAEMATOLOGICA

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

(2016) Lorenzo Falchi et al.   Mediterranean Journal of Hematology and Infectious Diseases

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

(2015) Michael Hallek   AMERICAN JOURNAL OF HEMATOLOGY

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) C. Sun et al.   BLOOD

Racial differences in three major NHL subtypes: Descriptive epidemiology

(2015) Yang Li et al.   Cancer Epidemiology

Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century

(2015) Dianne Pulte et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

(2015) K A Rogers et al.   LEUKEMIA

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

(2014) Gabriel Mannis et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

(2014) M. Levade et al.   BLOOD

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

(2014) J. A. Woyach et al.   BLOOD

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

(2014) S E M Herman et al.   LEUKEMIA

The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era

(2014) Chadi Nabhan et al.   LEUKEMIA & LYMPHOMA

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib: a paradigm shift in management of CLL

(2014) Talha Badar et al.   Expert Review of Hematology

2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension

(2013) Giuseppe Mancia et al.   BLOOD PRESSURE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guideline on the management of bleeding in patients on antithrombotic agents

(2012) Mike Makris et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA